Free Trial

Curaleaf (OTCMKTS:CURLF) Shares Gap Down - What's Next?

Curaleaf logo with Medical background

Key Points

  • Curaleaf Holdings, Inc. shares gapped down from $2.86 to $2.56 prior to trading, with a recent trading price of $2.77.
  • Cormark upgraded the stock from a "hold" to a "moderate buy" rating, contributing to an overall average rating of "Strong Buy" among analysts.
  • The company reported earnings per share of ($0.06) for the latest quarter, surpassing the consensus estimate and projecting a forecast of -0.25 EPS for the current fiscal year.
  • Five stocks we like better than Curaleaf.

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) shares gapped down prior to trading on Thursday . The stock had previously closed at $2.86, but opened at $2.56. Curaleaf shares last traded at $2.77, with a volume of 309,401 shares changing hands.

Wall Street Analyst Weigh In

Separately, Cormark raised shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Strong Buy".

Get Our Latest Research Report on Curaleaf

Curaleaf Trading Down 4.5%

The firm has a market capitalization of $1.83 billion, a PE ratio of -8.54 and a beta of 0.78. The firm's fifty day moving average is $2.04 and its two-hundred day moving average is $1.30. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.47 and a quick ratio of 0.70.

Curaleaf (OTCMKTS:CURLF - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%. On average, equities analysts predict that Curaleaf Holdings, Inc. will post -0.25 EPS for the current fiscal year.

About Curaleaf

(Get Free Report)

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Curaleaf Right Now?

Before you consider Curaleaf, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.

While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.